R. B.
October 2007
Red Herring;10/7/2007, Vol. 4 Issue 29, p78
Trade Publication
The article features Satiety, a medical device company included in "Red Herring's" top 100 list for 2007. The company is located in Palo, Alto, California. It was founded in 2001. Its chief executive officer (CEO) is Greg Patterson. Among its key investors are ABS Ventures, Morgenthaler Ventures, Dr. Tom Fogarty, Three Arch Ventures and Venrock. The company is developing a medical device for the treatment of obesity. The small device is introduced through the mouth, and once down the throat, a vacuum grabs tissue from the front and back of the stomach, forming a pouch.


Related Articles

  • MDD's Fast Facts. Harris, Michael J. // Medical Device Daily;3/14/2011, Vol. 15 Issue 49, p2 

    The author comments on the impact of another obesity drug failure on the medical device sector.

  • Harley. Patterson, Greg // Descant (0382909X);Summer2008, Vol. 39 Issue 2, p72 

    The short story "Harley" by Greg Patterson is presented.

  • Financings roundup.  // Medical Device Daily;7/18/2007, Vol. 11 Issue 137, p3 

    The article presents financing-related news briefs in the U.S. Satiety has closed a $30 million Series D financing led by new investor Skyline Ventures. Brendan Technologies, based in Carlsbad, California, has secured a bridge financing of $600,000, led by Little Bear Investments and facilitated...

  • Market savvy. Horton, Kathleen // Pharmaceutical Executive;Sep97, Vol. 17 Issue 9, p158 

    Focuses on the report `Therapeutic Approaches to the Treatment of Obesity,' which examines the market conditions for weight-reducing pharmaceuticals. Key issues in developing novel anti-obesity agents; Other contents of the report; Contact information.

  • Back to basics: Three squares a day.  // Environmental Nutrition;Nov92, Vol. 15 Issue 11, p3 

    Reports that the best way to lose weight is to go back to eating three square meals a day instead of skipping meals or eating five to six small meals a day. Effects of skipping meals; Small meals.

  • Weight loss for obese people: What works?  // HealthFacts;Jan97, Vol. 22 Issue 1, p3 

    Focuses on the declaration of obesity as a chronic disease to be treated with drugs. Results of a review of studies in which participants underwent drug and/or behavioral therapy; Warning against people embarking on drug therapy; Potential side effects.

  • An up-and-coming drug for the obese.  // Modern Medicine;Jan96, Vol. 64 Issue 1, p33 

    Reports on the US Food and Drug Administration's (FDA) approval of an anti-obesity drug which is used in 65 other countries. Drug composition; Effectiveness.

  • New obesity drug should be reserved for patients who reach a plateau or who have trouble...  // Modern Medicine;Jun96, Vol. 64 Issue 6, p14 

    Reports on a drug called dexfenfluramine hydrochloride claimed to be effective for the treatment of obesity. Reduction of weight in obese patients who have reached a plateau in their weight; Clinical studies on the drug; Effectiveness of the drug; Recommended dosage of the drug.

  • First new drug in 20 years to help fight obesity.  // Modern Medicine;Jun96, Vol. 64 Issue 6, p40 

    Reports on a drug called dexfenfluramine hydrochloride claimed to be effective in the treatment of pathological obesity. Promotion of weight loss; Maintenance of weight loss; Recommendation for patients with chronic diseases such as diabetes, hypertension and hypercholesterolemia.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics